The clinical value of monitoring residual CD26+ LSCs in addition to standard molecular response still needs to be validated; however, our data reinforce the concept that measurement of BCR-ABL1 transcript only may not reflect the actual residual CML LSCs burden. This evidence concerns the gene DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive.